Sorafenib and Regorafenib in HBV- or HCV-positive hepatocellular carcinoma patients: Analysis of RESORCE and SHARP trials.

Casadei Gardini, A
Frassineti, Gl
Foschi, Fg
Ercolani, G
Ulivi, P.

Publication date

January 2017

DOI

10.1016/j.dld.2017.04.022

Abstract

Different treatment strategy based on tumor etiology. Future studies should be made to evaluate if the use of first line regorafenib in HBV-positive HCC patients may be the best strategy for improvement the outcome of these patient

Extracted data

We use cookies to provide a better user experience.

Data Protection

Sorafenib and Regorafenib in HBV- or HCV-positive hepatocellular carcinoma patients: Analysis of RESORCE and SHARP trials.

Abstract

Extracted data

Sorafenib and Regorafenib in HBV- or HCV-positive hepatocellular carcinoma patients: Analysis of RESORCE and SHARP trials.

Abstract

Extracted data

Related items

Related items